ResMed Inc. RMD
NYSE
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 5.73B | 5.65B | 5.54B | 5.40B | 5.26B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 5.73B | 5.65B | 5.54B | 5.40B | 5.26B |
| Cost of Revenue | 2.20B | 2.18B | 2.10B | 2.09B | 2.07B |
| Gross Profit | 3.53B | 3.48B | 3.44B | 3.31B | 3.18B |
| SG&A Expenses | 1.13B | 1.12B | 1.09B | 1.06B | 1.02B |
| Depreciation & Amortization | 57.47M | 57.47M | 59.97M | 59.21M | 58.32M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.78B | 3.73B | 3.61B | 3.55B | 3.49B |
| Operating Income | 1.95B | 1.92B | 1.92B | 1.85B | 1.76B |
| Income Before Tax | 2.01B | 1.92B | 1.90B | 1.82B | 1.74B |
| Income Tax Expenses | 418.61M | 396.12M | 383.74M | 332.81M | 302.96M |
| Earnings from Continuing Operations | 1.59K | 1.52K | 1.52K | 1.49K | 1.44K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 1.59B | 1.52B | 1.52B | 1.49B | 1.44B |
| EBIT | 1.95B | 1.92B | 1.92B | 1.85B | 1.76B |
| EBITDA | 2.13B | 2.10B | 2.12B | 2.02B | 1.94B |
| EPS Basic | 11.01 | 10.47 | 10.41 | 10.16 | 9.81 |
| Normalized Basic EPS | 8.68 | 8.45 | 8.37 | 7.94 | 7.57 |
| EPS Diluted | 10.98 | 10.43 | 10.37 | 10.11 | 9.77 |
| Normalized Diluted EPS | 8.66 | 8.42 | 8.34 | 7.91 | 7.54 |
| Average Basic Shares Outstanding | 578.88M | 582.07M | 583.84M | 585.22M | 586.18M |
| Average Diluted Shares Outstanding | 580.48M | 583.97M | 586.03M | 587.53M | 588.64M |
| Dividend Per Share | 2.46 | 2.40 | 2.33 | 2.26 | 2.19 |
| Payout Ratio | 22.40% | 22.95% | 22.39% | 22.25% | 22.31% |